CAN CLINICAL, BIOLOGICAL OR PHARMACOLOGICAL MARKERS PREDICT SUSTAINED RESPONSE TO INFLIXIMAB? A RETROSPECTIVE ANALYSIS OF ACCENT 1
(1) Janssen Biologics BV
(2) University of Chicago
(3) Centocor Orthobiotech Inc.
(4) Centocor Research & Development, Inc.
(5) University Hospital Gasthuisberg
This item was part of the IBD II session at UEG Week Stockholm 2011
This item can be cited as: Gut 2011; 60 (Suppl 3) A296
You may be interested in:
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013
English, Presentation, Clinical aspects, Medical management, Colon, Inflammatory bowel disease, 2010